Innoviva, Inc.: Pioneering the Future of Pharmaceutical Products Innoviva, Inc., a California-based pharmaceutical company, is steadily making a name for itself through its innovative product development and commercialization techniques. Its flagship products include RELVAR/BREO ELLIPTA, ANORO ELLIPTA, and TRELEGY ELLIPTA, all of which are once-daily combination medicines designed to tackle chronic obstructive pulmonary disease and asthma through ingenious combinations of long-acting muscarinic antagonists (LAMA), inhaled corticosteroids (ICS), and long-acting beta2 agonists (LABA). The company's strategic partnership with Sarissa Capital Management LP has been a key driving force behind its success. Furthermore, Innoviva, Inc. has a LABA collaboration agreement with Glaxo Group Limited to develop and commercialize its products globally, solidifying its presence in the international market. Incorporated in 1996, Innoviva, Inc. was formerly known as Theravance, Inc. before undergoing a rebranding initiative in January 2016 to reflect its rapidly evolving pharmaceutical landscape. Today, the company's headquarters in Burlingame, California, boasts a team of dedicated professionals tirelessly working towards providing the best precision medicine to those who need it most.
Innoviva, Inc.'s ticker is INVA
The company's shares trade on the NASDAQ stock exchange
They are based in Burlingame, California
There are 1-10 employees working at Innoviva, Inc.
It is https://www.inva.com/
Innoviva, Inc. is in the Healthcare sector
Innoviva, Inc. is in the Biotechnology industry
The following five companies are Innoviva, Inc.'s industry peers: